Pulse Biosciences (Pulse Biosciences) Cash per Share : $0.62 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Pulse Biosciences's Cash per Share for the quarter that ended in Mar. 2024 was $0.62.

Pulse Biosciences Cash per Share Historical Data

The historical data trend for Pulse Biosciences's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences Cash per Share Chart

Pulse Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

1.20

0.79

0.95

1.62

0.79

Pulse Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															1.42	1.06	0.90	0.79	0.62

Pulse Biosciences Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Pulse Biosciences's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	44.365	/	56.08
	=	0.79

Pulse Biosciences's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	34.885	/	56.16
	=	0.62

Pulse Biosciences (NAS:PLSE) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Pulse Biosciences Cash per Share Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulse Biosciences (Pulse Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

6L8:Germany

Address

3957 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.pulsebiosciences.com

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Executives

Robert W Duggan	director, 10 percent owner	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy	officer: Chief Commercial Officer	50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner	officer: CFO & EVP Admin. and Finance	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray	director	C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono	director
Ed Ebbers	officer: EVP & GM, Dermatology	3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D	director	C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg	director	12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow	officer: CFO & SVP Admin. and Finance	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588